Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

29 trials with published results (20%)

Research Maturity

90 completed trials (62% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

7.5%

11 terminated out of 146 trials

Success Rate

89.1%

+2.6% vs benchmark

Late-Stage Pipeline

12%

18 trials in Phase 3/4

Results Transparency

32%

29 of 90 completed with results

Key Signals

29 with results89% success11 terminated

Data Visualizations

Phase Distribution

89Total
Not Applicable (48)
Early P 1 (1)
P 1 (12)
P 2 (10)
P 3 (5)
P 4 (13)

Trial Status

Completed90
Recruiting19
Unknown17
Terminated11
Withdrawn4
Not Yet Recruiting2

Trial Success Rate

89.1%

Benchmark: 86.5%

Based on 90 completed trials

Clinical Trials (146)

Showing 20 of 20 trials
NCT01143454Recruiting

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT07541833RecruitingPrimary

Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)

NCT03057561Not ApplicableCompleted

Efficacy of Dotarem® (Gd-DOTA) Versus Gadovist® (Gd-DO3A-butrol) for Late Gadolinium Enhancement Cardiac Magnetic Resonance

NCT07479641Phase 1RecruitingPrimary

A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants

NCT01143519Completed

Study of the Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage

NCT07308704RecruitingPrimary

A Study Of Deep Learning For Echo Analysis, Tracking, And Evaluation

NCT06865482Recruiting

Clinical Course Of Disease In Participants With FA-CM

NCT07272330Phase 1CompletedPrimary

A Phase I Trial on the Relative Bioavailability and Food Effect of HRS-1893 Tablets in Healthy Subjects

NCT00335036Not ApplicableTerminated

Pediatric Lead Extractability and Survival Evaluation (PLEASE)

NCT05371496Phase 2Enrolling By InvitationPrimary

Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction

NCT07428031Not Yet RecruitingPrimary

French Registry: Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy

NCT07116525Not ApplicableRecruiting

A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter

NCT05507879Recruiting

TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer

NCT02962661Phase 1RecruitingPrimary

Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

NCT04520347Enrolling By Invitation

IVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry

NCT06483802Phase 1Withdrawn

A Study of ASP2016 in Adults Who Have Heart Disease Associated With Friedreich Ataxia

NCT01648634Phase 3Completed

Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy

NCT02641145Not ApplicableRecruiting

Molecular Imaging of Primary Amyloid Cardiomyopathy

NCT06609174Not ApplicableCompletedPrimary

AI-SCREENDCM Decentralized Clinical Trial - Pilot Study

NCT01261065Phase 4Completed

Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure

Scroll to load more

Research Network

Activity Timeline